BioLineRx Ltd. (BLRX)

NasdaqCM: BLRX · 실시간 가격 · USD

2.83

+0.06 (2.17%)

종가 기준: Aug 12, 2026, 3:30 PM

2.17% (1D)

데이터 없음

매수호가	2.2
시가총액	12.73M
매출 (ttm)	1.4M
순이익 (ttm)	-7.9M
베타	0.71
EPS (ttm)	0
P/E (ttm)	n/a
선행 P/E	-4.42
P/B (ttm)	0.79
P/S (ttm)	9.08
Earnings Date	Mar 16, 2022

매도호가	2.31
거래량	8,291
평균 거래량 (20일)	47,243
시가	2.69
전일 종가	2.77
일중 범위	2.69 - 3.00
52주 범위	2.15 - 4.56
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

BLRX 소개

BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed ...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Jul 27, 2011

직원 수 20

상장 거래소 NasdaqCM

티커 BLRX

웹사이트 https://www.biolinerx.com

전체 기업 정보

재무 실적

2025년 BioLineRx의 매출은 1.18M로, 전년 28.94M 대비 -95.92% 감소했습니다. 순이익은 -1.18M로, -87.26% 감소했습니다.

재무제표

어닝 서프라이즈

BioLineRx가 Mar 26, 2024에 분기 실적을 발표했습니다:

매출 $477K 예상치 하회 $0, 및 87.06% 전년 대비 성장.

EPS -3.58 예상치 상회 5.22, 및 40.33% 전년 대비 성장.

다음 실적 발표

BioLineRx Ltd.의 실적 발표 예정일은 Mar 16, 2022, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

2개월 전 · GuruFocus.com

BioLine Rx Ltd (BLRX) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ...

BioLine Rx Ltd (BLRX) reports increased revenue and APHEXDA sales, while navigating a net loss and competitive pressures in the glioblastoma treatment landscape.

2개월 전 · InvestorsHub

BioLineRx Shares Advance After First Patient Enrolled in GLIX1 Cancer Study (BLRX)

BioLineRx Ltd. (NASDAQ:BLRX) reported first-quarter 2026 financial results on Wednesday, shortly after announcing that the first patient had been dosed in its Phase 1/2a clinical study evaluating GLIX...

4개월 전 · GuruFocus.com

BioLine Rx Ltd (BLRX) Full Year 2025 Earnings Call Highlights: Navigating Challenges and ...

Despite a significant revenue drop, BioLine Rx Ltd (BLRX) focuses on innovative treatments and maintains a strong cash position to drive future growth.

8개월 전 · GuruFocus.com

BioLine Rx Ltd (BLRX) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...

BioLine Rx Ltd (BLRX) reports reduced net loss and strategic developments in cancer treatment, bolstered by a strong cash position.

BioLineRx Ltd. (BLRX)